Surgery in the age of biologics

作     者：Daniel J.Wong Eve M.Roth Joseph D.Feuerstein Vitaliy Y.Poylin 

作者机构：Department of SurgeryDivision of Colon&Rectum SurgeryBeth Israel Deaconess Medical CenterHarvard Medical SchoolBostonMassachusettsUSA Department of MedicineDivision of GastroenterologyBeth Israel Deaconess Medical CenterHarvard Medical SchoolBostonMassachusettsUSA 

出 版 物：《Gastroenterology Report》 (胃肠病学报道（英文）)

年 卷 期：2019年第7卷第2期

页      面：77-90,I0001页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：National Heart  Lung  and Blood Institute  NHLBI  (T32HL007734) 

主　　题：Biologics inflammatory bowel disease surgery review 

摘      要：Since the introduction of the first anti-tumor necrosis factor antibodies in the late 1990s,biologic therapy has revolutionized the medical treatment of patients with inflammatory bowel disease(IBD).Nevertheless,surgery continues to play a significant role in treating IBD *** of intestinal resection in patients with Crohn’s disease or colectomy in ulcerative colitis are reducing but not substantially over the long *** increasing variety of biologic medications are now available to treat IBD patients in various clinical ***,a number of questions persist about how biologic medications affect the need for surgery and overall course in IBD *** the trend for earlier and more frequent use of biologic medications in IBD patients,a working knowledge of the effects of these medications on surgical decision-making and outcomes is essential for the practicing colorectal surgeon and *** review seeks to summarize the relevant literature surrounding biologic use and IBD surgery with a focus on the effect of biologics on the frequency,type and complications of surgery in this‘age of biologics’.